People | September 04, 2024
Enzene appoints new site lead of biologics manufacturing
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
New Phase II data show vast majority of patients experiencing no relapses or disability progression
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The grant is designated for the research and development of Pyronaridine
Subscribe To Our Newsletter & Stay Updated
